Method of blood coagulation

专利摘要:
A concentrate of blood coagulation Factor VIII:C is obtained in high yield by fractionation of blood plasma with a sequence of adsorption steps employing two different water-insoluble, cross-linked polyelectrolyte copolymers, each in the presence of exogenous heparin.
公开号:SU1375116A3
申请号:SU833611812
申请日:1983-06-21
公开日:1988-02-15
发明作者:Харпстер Джонсон Джон
申请人:Монсанто Компани (Фирма)；
IPC主号:

专利说明:

one
13751
The invention relates to medicine, in particular to the field of blood fractionation and the release of blood clotting preparations.
The purpose of the invention is to increase the yield of the target product - the USh factor: C.
The goal is achieved by functioning blood plasma at certain pH values using two water-insoluble crosslinked polyelectrolyte copolymers used in the presence of exogenous heparin,
The invention is illustrated by the following examples.
Example 1. Human blood is poured into plastic bags containing an anticoagulant — CPDA-1 (citrate, phosphate, dextrasic anticoagulant. With adepine — anticoagulant nt-USA). Separate the plasma by centrifugation at a strength of 500–4000 g for 4 h, at 20-24 ° C. 200 ml portions of plasma are frozen at.
Self-frozen plasma is subjected to adsorption at room temperature using two water-insoluble cross-linked polyelectrolyte copolymers (resins) in the presence of exogenous heparin. Resin A is a copolymer of equimolar amounts of ethylene and maleic anhydride, crosslinked with 5 mol.% Methylaminobispropylamine, containing 90 mol.% Of terminal dimethylaminopropylimide groups. Resin B is a copolymer of ethylene and maleic anhydride, crosslinked with 5 mol.% Dimethylaminopropylimide, containing 5 mol,% of terminal dimethylaminopropyiimide groups,
In resin B, all free carbo-: xyl and anhydride groups are protected by methoxypropylamine.
Prior to use, resin B is pretreated as follows.
12 g of resin is dispersed in 200 ml of 0.154 M NaCl containing 0.1% cattle serum albumin (ASK). The pH is adjusted to 4.0 using 1.0 M citric acid. Dispersing is carried out for 3-5 minutes with stirring. The suspension is filtered, the filtrate is discarded. A wet resin filter cake is obtained.
Q 5
0 5
About d
0 5
five
five
162
Ru is again dispersed in 200 ml of NaCl / ACK. When added with stirring 1.0 M NaOH, the pH is adjusted to 5.8. Stirring is continued for another 10 minutes. The slurry is filtered and the wet cake is used for the subsequent fractionation.
All solutions used with. the elution and in the process of fractionation contain 0.1% ASA,
Porcine heparin sodium salt is used in the form of a solution of units / m in physiological solution.
The fractionation process is carried out as follows.
One bag (ie 200 ml) of freshly frozen plasma is quickly thawed; by placing it in a stirred water bath at 3 ° C. Then, 1 ml of heparin solution (i.e., 200 units) is added to the mixture, the mixture is stirred for 3-5 minutes. A sample is taken for the coagulation test (volume and time are recorded). Control samples are identical to those tested, but without the addition of heparin in the plasma.
70 mg of resin A are added to the plasma, the pH value is adjusted to 8.0 with 1 M NaOH, maintaining this pH value while stirring the mixture for 20 minutes. Then the mixture is filtered, the resulting filtrate contains most of the activity of factor VIII; C. The wet resin cake was washed with 20 ml of distilled water, stirred for 5 minutes, filtered, and the two obtained filtrate were collected and tested for factor VIII: C. A volume of activity is recorded to calculate the total number of coagulation units.
To the filtrate is added pretreated resin B (12 g),. by adding 1 M citric acid, the pH is adjusted to 5.8 and the suspension is stirred for 20 minutes, maintaining a pH of 5.8. The suspension is filtered, the precipitate is washed with 200 ml of 0.002 M NaCl. Then the precipitate is dispersed in 200 ml of 0.3 M NaCl, adjusted to pH 5.8, the suspension is stirred for 5 minutes, filtered again, the precipitate is washed with an additional 200 ml of 0.3 M NaCl, and the filtrate is discarded.
The filtered precipitate is again dispersed in 200 ml of elution solvent containing 1.5 M NaCl, 0, .1 M lysine and 0.1% ASA. The pH is adjusted to 6.0 and the suspension is stirred.
20 minutes. The suspension is filtered and the precipitate is washed with 20 ml of elution solvent, after which a sample of the filtrate is taken for testing for coagulation, as indicated in the table. one
The filtrates containing 40–70% of the initial coagulation activity of the USh factor: С in a purified form are concentrated and partially desalted by passing through semipermeable membranes (Millipore Pellicon Cassette filtration system or Amicon III hollow fiber concentrator system.
The concentrated solution is freeze dried and packaged for storage.
Table 1 shows the results of several passes of fractionation using the collected plasma of stabilized SRDA, illustrating the beneficial effect of adding heparin to the plasma in combination with the use of resins A and B.
Determination of the USh factor; C is performed by indicating the start of the coagulation process. The second derivative of the coagulation rate (i.e., the rate of change of the coagulation rate) is measured. A plasma in which the USh: C factor is absent is used as a control, while ellagic acid.
The coagulation time at serial dilutions of the fractionated samples used is determined. The results obtained are expressed as a percentage of the release of the activity of the USh factor: C, based on the degree of activity of the originally collected plasma sample. The initial sample is considered to contain 1 unit of coagulation activity.
USh factor: With 1 ml. Each test was started with a total of 200 units of coagulation. Finally, the cumulated unit and the percentage release of activity after each resin treatment are recorded.
Example 2. The method is carried out as described in example 1, except that three different concentrations of heparin are added to the initial plasma before the Lik treatment with the filtrate before the treatment with resin B.
The results are presented in table. 2

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining USh factor: With blood coagulation by fractionation from blood by adsorption on a water-insoluble crosslinked polyelectrolyte copolymer, followed by elution of the target product from the adsorbent, characterized in that, in order to increase the yield of the target product, blood plasma at pH 8.0 is mixed with 0.035% by weight of a copolymer of ethylene and maleic anhydride crosslinked in the presence of 0.1- t, 0 IU / ml of heparin with 5 mol.% Methyl-., Minbisopropylamine containing 90 mol.% Of terminal dimethylaminopropylimide groups, followed by separation of the soup A connatant in which 6% of a copolymer of ethylene and small anhydride, crosslinked with 5 mol.% of methyliminobypropylamine containing 5 mol.% of terminal dimethyl aminoprosidine groups, is added at pH 5.8, while the free carboxyl and anhydride groups are blocked by the addition of methoxypropylamine. in the presence of 0.1-1.0 IU / ml heparin.
Table 1
Controls without heparin supplements
145 72,5 88
13768.5 76
10653.0 41
44.0 38.0 20.5
144
105
127 ± 20
72.0
52.5
63.7i10.1
84 93 76.0 ± 21.0
Samples treated with heparin (1.03 ad / ml)
171 190 166 164 204 188 ± 27.0
85.5
95.0
83.0
82.0
102.0
93.9 ± 13.5
118
120 112 109 139 120 ± 12.0
In terms of the activity of the original plasma.
table 2
The amount of heparin added. Activity / ml
1.0 J 0.5 0.1
Activity highlighted from
resin A,% 91 ± 6 81 96 ± 14
Cumulated activity
isolated from resin B,% 53 ± 17 48 5315
One series of tests.
I
Compiled by A. Agureyev Editor M. Nedoluzhenko Tehred L. Serdyukova Proofreader M. Maksimishinets
Order 622/57 Draw 65 Subscription
VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, st. Project, 4
Continuation of table 1
84 93 76.0 ± 21.0
ohm (1.03 ad / ml)
118
120 112 109 139 20 ± 12.0
42.0 46.5 38.2 + 10.4
59.0 60.0 56.0 54.5 69.5 59.8 ± 5.9

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1375116A3|1988-02-15|Method of blood coagulation

---

US4073886A|1978-02-14|Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene

---

US4376707A|1983-03-15|Process for the removal of urea from blood wash fluids and blood

---

US5099003A|1992-03-24|Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii

---

EA023615B1|2016-06-30|Method for isolating osteopontin using concentrated feeds

---

FI95136B|1995-09-15|Method for purifying annexins

---

Dike et al.1972|The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate containing factor VII

---

NL8601814A|1987-02-02|METHOD FOR EXTRACTING PROTEINS FROM MILK, PRODUCTS, USES OF THE METHOD AND PHARMACEUTICAL PREPARATIONS.

---

DE2640387C3|1981-01-22|Tissue-specific protein and method for its production

---

SU841572A3|1981-06-23|Method of preparing protein blood components

---

SU736861A3|1980-05-25|Method of preparing serous albumin fractions

---

SU1367837A3|1988-01-15|Method of producing agent selectively inhibiting growth or reproduction of normal and leukemia cells of myeloids

---

KR0168866B1|1999-01-15|Polyhemoglobin stabilized by purin derivatives and glutathione

---

DE3013724A1|1981-10-15|NEW PROTEIN PP | 9 |, METHOD FOR ITS ENRICHMENT AND PRODUCTION AND ITS USE

---

CN111569143B|2021-05-14|Snake venom prothrombin activator and rapid hemostatic material based on same

---

JPH09506256A|1997-06-24|Purification of vitamin K-dependent protein by membrane chromatography

---

US4067964A|1978-01-10|Antihemophilic agent and process for its manufacture

---

CA1224777A|1987-07-28|Antitumor glycoprotein substance and its preparation

---

US5403914A|1995-04-04|Biological mediators of immune functions

---

JP2548822B2|1996-10-30|Glycoprotein derived from Mackerel barley, method for producing the same and immunomodulator containing the same

---

SU513595A3|1976-05-05|The method of selection orgoteina

---

Deisseroth et al.1969|The purification and crystallization of beef erythrocyte catalase

---

WO1984002651A1|1984-07-19|Purification of antihemophilia factor viii by precipitation with zinc ions

---

Thies et al.1988|Selective removal of low‐density lipoproteins from plasma by polyacrylate‐coated Fractogel in vitro and in experimental extracorporeal perfusion

---

US4471112A|1984-09-11|Heparin polyelectrolyte polymer complex

同族专利:

---

公开号 | 公开日

---

AU1628483A|1984-01-05|

---

EP0098256A2|1984-01-11|

---

US4397841A|1983-08-09|

---

EP0098256B1|1988-08-31|

---

DE3377872D1|1988-10-06|

---

AU555045B2|1986-09-11|

---

JPH0339080B2|1991-06-12|

---

ZA834691B|1984-06-27|

---

HU189708B|1986-07-28|

---

AT36861T|1988-09-15|

---

ES8500744A1|1984-11-01|

---

JPS5910523A|1984-01-20|

---

EP0098256A3|1985-10-23|

---

ES523593A0|1984-11-01|

---

CA1197780A|1985-12-10|

---

IL69102A|1987-03-31|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3555001A|1969-05-29|1971-01-12|Monsanto Co|Process for the fractionation of plasma and serum using water-insoluble polyelectrolytes containing diloweralkylaminoloweralkylimide groups|

---

US3803115A|1972-05-17|1974-04-09|Baxter Laboratories Inc|Stabilization of ahf using heparin|

---

NL7708005A|1976-07-22|1978-01-24|Monsanto Co|PROCESS FOR THE PREPARATION OF SERUM ALBUMIN.|

---

ES471858A1|1977-07-25|1979-02-01|Monsanto Co|Non-activating polyelectrolytes and their use in a method for separation of blood coagulation factors.|

---

US4081432A|1977-07-25|1978-03-28|Monsanto Company|Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers|

---

CA1074698A|1977-12-19|1980-04-01|Gail A. Rock|Method of collecting anti-hemophilic factor viii from blood and blood plasma|

---

US4278594A|1979-06-19|1981-07-14|David Amrani|Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor and fibronectin from blood plasma|

---

SE448945B|1979-12-20|1987-03-30|Blombaeck E G B|PROCEDURE FOR CLEANING AND / OR CONCENTRATION OF THE FACTOR VIII COMPLEX|

---

US4289691A|1980-01-18|1981-09-15|The Canadian Red Cross Society|Method of obtaining intermediate purity factor VIII|

---

US4361509A|1981-12-14|1982-11-30|Scripps Clinic And Research Foundation|Ultrapurification of factor VIII using monoclonal antibodies|US4495175A|1982-08-05|1985-01-22|University Of Rochester|Preparation of highly purified human antihemophilic factor|

---

IE80858B1|1983-03-31|1999-04-21|Scripps Research Inst|New factor viii coagulant polypeptides|

---

US4508709A|1983-12-05|1985-04-02|Armour Pharmaceutical Company|Process for purifying factor VIII:C|

---

GB8403473D0|1984-02-09|1984-03-14|Special Trustees For St Thomas|Purification of factor viii|

---

US5149787A|1984-05-22|1992-09-22|The Blood Center Research Foundation|Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing|

---

US4675385A|1985-03-27|1987-06-23|Alpha Therapeutic Corporation|Isolation of human plasma procoagulant protein factor VIII from biological factors|

---

GB2178533B|1985-07-22|1989-07-19|Asahi Chemical Ind|Analytical method of enzyme precursors and device therefor|

---

JPS62191042A|1986-02-17|1987-08-21|Kanegafuchi Chem Ind Co Ltd|Blood coagulation factor viii adsorbent and method for purifying blood coagulation factor viii using same|

---

GB8708181D0|1987-04-06|1987-05-13|Wensley R|Extraction of protein from blood|

---

US4795806A|1987-07-16|1989-01-03|Miles Laboratories, Inc.|Phospholipid affinity purification of Factor VIII:C|

---

ES2045167T5|1987-10-23|1996-07-01|Centre Regional De Transfusion|PREPARATION OF HUMAN FACTOR IX CONCENTRATE OF HIGH PURITY AND OTHER PLASMA PROTEINS.|

---

GB8913183D0|1989-06-08|1989-07-26|Central Blood Lab Authority|Chemical products|

---

USH1509H|1989-06-09|1995-12-05|Eran; Harutyun|Heparin enhanced process for separating antihemophilic factorand fibronectin from cryoprecipitate|

---

US5110907A|1989-08-01|1992-05-05|Alpha Therapeutic Corporation|Factor viii complex purification using heparin affinity chromatography|

---

FR2657884B1|1990-02-05|1994-09-02|Tm Innovation|PROCESS FOR THE PREPARATION OF HUMAN FACTOR VIII AND FACTOR VIII ANALOGS.|

---

UY30193A1|2007-03-07|2008-10-31|Mary Lopretti|COMPOSITIONS CONTAINING OLIGOMEROS DEL POLI-2-AMINO-2-DEOXIGLUCOPIRANOSA) IN SOLUTION OF MODIFIED PHENOLS OF LIGNINA AND ITS USES.|

---

ES2647925T3|2011-05-12|2017-12-27|Csl Behring Gmbh|Methods to reduce adverse events caused by pharmaceutical preparations comprising proteins derived from plasma|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/392,929|US4397841A|1982-06-28|1982-06-28|Production of blood coagulation factor VIII:C|

---